Clinical Trial Update: Study of Ravulizumab in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS) [Phase 3]

View source ↗

Summary

Phase 3 trial in children and adolescents with atypical hemolytic uremic syndrome (aHUS) completed, with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atypical Hemolytic Uremic Syndrome

Drugs mentioned

• Ravulizumab (ravulizumab)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Atypical Hemolytic Uremic Syndrome (aHUS) | Phase 3 | Status: COMPLETED | Results posted: 2020-09-16